Tea Skaaby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tea Skaaby has a total of 673 co-authors. Here are the top co-authors by number of shared publications:
- Allan Linneberg
Center for Clinical Research and Prevention, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
66 shared publications - Betina Heinsbaek Thuesen
Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
37 shared publications - Torben Jørgensen
Center for Clinical Research and Prevention, Copenhagen University Hospital–Bispebjerg and Frederiksberg, 2000 Copenhagen, Denmark
27 shared publications Lise Lotte Nystrup Husemoen
Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup, Denmark
16 shared publications- Torben Hansen
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
14 shared publications - Oluf Pedersen
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
13 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 11 January 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (6) , 1047-1054
Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK
Background: The lack of attention paid to chronic hand eczema (CHE) and the lack of a specific International Classification of Diseases code for it may have limited assessment of its prevalence. To date, prevalence estimates have primarily been derived from (partly small) single-country studies. Objectives: To estimate the annual prevalence of self-reported physician-diagnosed CHE across sociodemographic characteristics in adults living in Canada, France, Germany, Italy, Spain and the UK. Methods: In the observational Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden (CHECK) study, a questionnaire was administered to adults aged 18–69 years in the general population, recruited through online panels. Quotas and minor weighting adjustments were performed to ensure that the participants were representative of the general population with regard to sex, age, region, employment status, urban/rural setting and – in the UK only – ethnicity. Additional weights were applied to account for population size differences when aggregating country results. Information on self-reported physician-diagnosed CHE was collected. CHE was defined, in accordance with the European Society of Contact Dermatitis, as having had hand eczema continuously for ≥ 3 months or at least two flares in the past 12 months. The annual prevalence of CHE was determined for each country, and by subgroups of sex, age, employment and urban/rural setting. Results: Of 60 131 participants, 2847 self-reported physician-diagnosed CHE, yielding an annual prevalence of 4.7% [95% confidence interval (CI) 4.6–4.9]. Subgroup analyses revealed that the prevalence of CHE was significantly higher in women than in men [5.6% (95% CI 5.4–5.9) vs. 3.8% (95% CI 3.6–4.1); P < 0.001], in employed vs. unemployed people [5.3% (95% CI 5.1–5.6) vs. 3.3% (95% CI 3.1–3.6); P < 0.001] and in urban vs. rural residents [5.0% (95% CI 4.8–5.2) vs. 3.7% (95% CI 3.4–4.1); P < 0.001). Prevalence was highest in those aged 30–39 years (6.5%, 95% CI 6.0–7.0) and lowest in those aged 60–69 years (2.6%, 95% CI 2.3–3.0). Conclusions: This large multinational study is the first to assess the prevalence of CHE in Europe and Canada using a consistent definition across a broad geographical population. This study reveals that CHE is a common skin disease with annual prevalence of 4.7%, with a higher prevalence in women, people aged 30–39, employed people and those living in urban areas.
- 11 January 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (6) , 1047-1054
Top Cited PapersOpen AccessPrevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK
Background: The lack of attention paid to chronic hand eczema (CHE) and the lack of a specific International Classification of Diseases code for it may have limited assessment of its prevalence. To date, prevalence estimates have primarily been derived from (partly small) single-country studies. Objectives: To estimate the annual prevalence of self-reported physician-diagnosed CHE across sociodemographic characteristics in adults living in Canada, France, Germany, Italy, Spain and the UK. Methods: In the observational Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden (CHECK) study, a questionnaire was administered to adults aged 18–69 years in the general population, recruited through online panels. Quotas and minor weighting adjustments were performed to ensure that the participants were representative of the general population with regard to sex, age, region, employment status, urban/rural setting and – in the UK only – ethnicity. Additional weights were applied to account for population size differences when aggregating country results. Information on self-reported physician-diagnosed CHE was collected. CHE was defined, in accordance with the European Society of Contact Dermatitis, as having had hand eczema continuously for ≥ 3 months or at least two flares in the past 12 months. The annual prevalence of CHE was determined for each country, and by subgroups of sex, age, employment and urban/rural setting. Results: Of 60 131 participants, 2847 self-reported physician-diagnosed CHE, yielding an annual prevalence of 4.7% [95% confidence interval (CI) 4.6–4.9]. Subgroup analyses revealed that the prevalence of CHE was significantly higher in women than in men [5.6% (95% CI 5.4–5.9) vs. 3.8% (95% CI 3.6–4.1); P < 0.001], in employed vs. unemployed people [5.3% (95% CI 5.1–5.6) vs. 3.3% (95% CI 3.1–3.6); P < 0.001] and in urban vs. rural residents [5.0% (95% CI 4.8–5.2) vs. 3.7% (95% CI 3.4–4.1); P < 0.001). Prevalence was highest in those aged 30–39 years (6.5%, 95% CI 6.0–7.0) and lowest in those aged 60–69 years (2.6%, 95% CI 2.3–3.0). Conclusions: This large multinational study is the first to assess the prevalence of CHE in Europe and Canada using a consistent definition across a broad geographical population. This study reveals that CHE is a common skin disease with annual prevalence of 4.7%, with a higher prevalence in women, people aged 30–39, employed people and those living in urban areas.
- Open Access
- 12 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0304145
Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome
Background: Reverse causation is a challenge in many drug-cancer associations, where the cancer symptoms are potentially mistaken for drug indication symptoms. However, tools to assess the magnitude of this type of bias are currently lacking. We used a simulation-based approach to investigate the impact of reverse causation on the association between the use of topical tacrolimus and cutaneous T-cell lymphoma (CTCL) in a multinational, population-based study using topical corticosteroids (TCS) as comparator. Methods: We used a multistate model to simulate patients’ use over time of a first- (TCS) and second-line treatment (topical tacrolimus), onset of atopic dermatitis (indication for drugs) and CTCL (the studied outcome). We simulated different scenarios to mimic real-life use of the two treatments. In all scenarios, it was assumed that there was no causal effect of the first- or second-line treatment on the occurrence of CTCL. Simulated data were analysed using Cox proportional hazards models. Results: The simulated hazard ratios (HRs) of CTCL for patients treated with tacrolimus vs. TCS were consistently above 1 in all 9 settings in the main scenario. In our main analysis, we observed a median HR of 3.09 with 95% of the observed values between 2.11 and 4.69. Conclusions: We found substantial reverse causation bias in the simulated CTCL risk estimates for patients treated with tacrolimus vs. TCS. Reverse causation bias may result in a false positive association between the second-line treatment and the studied outcome, and this simulation-based framework can be adapted to quantify the potential reverse causation bias.
- 12 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0304145
Open AccessReverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome
Background: Reverse causation is a challenge in many drug-cancer associations, where the cancer symptoms are potentially mistaken for drug indication symptoms. However, tools to assess the magnitude of this type of bias are currently lacking. We used a simulation-based approach to investigate the impact of reverse causation on the association between the use of topical tacrolimus and cutaneous T-cell lymphoma (CTCL) in a multinational, population-based study using topical corticosteroids (TCS) as comparator. Methods: We used a multistate model to simulate patients’ use over time of a first- (TCS) and second-line treatment (topical tacrolimus), onset of atopic dermatitis (indication for drugs) and CTCL (the studied outcome). We simulated different scenarios to mimic real-life use of the two treatments. In all scenarios, it was assumed that there was no causal effect of the first- or second-line treatment on the occurrence of CTCL. Simulated data were analysed using Cox proportional hazards models. Results: The simulated hazard ratios (HRs) of CTCL for patients treated with tacrolimus vs. TCS were consistently above 1 in all 9 settings in the main scenario. In our main analysis, we observed a median HR of 3.09 with 95% of the observed values between 2.11 and 4.69. Conclusions: We found substantial reverse causation bias in the simulated CTCL risk estimates for patients treated with tacrolimus vs. TCS. Reverse causation bias may result in a false positive association between the second-line treatment and the studied outcome, and this simulation-based framework can be adapted to quantify the potential reverse causation bias.
- 3 January 2022
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 37 (7) , 713-722
Association of milk intake with hay fever, asthma, and lung function: a Mendelian randomization analysis
Background Previous observational studies have indicated a protective effect of drinking milk on asthma and allergy. In Mendelian Randomization, one or more genetic variants are used as unbiased markers of exposure to examine causal effects. We examined the causal effect of milk intake on hay fever, asthma, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) by using the lactase rs4988235 genotype associated with milk intake. Methods We performed a Mendelian Randomization study including 363,961 participants from the UK Biobank. Results Observational analyses showed that self-reported milk-drinkers vs. non-milk drinkers had an increased risk of hay fever: odds ratio (OR) = 1.36 (95% CI 1.32, 1.40, p < 0.001), asthma: OR = 1.33 (95% CI 1.38, 1.29, p < 0.001), yet a higher FEV1: β = 0.022 (SE = 0.004, p < 0.001) and FVC: β = 0.026 (SE = 0.005, p < 0.001). In contrast, genetically determined milk-drinking vs. not drinking milk was associated with a lower risk of hay fever: OR = 0.791 (95% CI 0.636, 0.982, p = 0.033), and asthma: OR = 0.587 (95% CI 0.442, 0.779, p = 0.001), and lower FEV1: β = − 0.154 (standard error, SE = 0.034, p < 0.001) liter, and FVC: β = − 0.223 (SE = 0.034, p < 0.001) liter in univariable MR analyses. These results were supported by multivariable Mendelian randomization analyses although not statistically significant. Conclusions As opposed to observational results, genetic association findings indicate that drinking milk has a protective effect on hay fever and asthma but may also have a negative effect on lung function. The results should be confirmed in other studies before any recommendations can be made.
- 3 January 2022
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 37 (7) , 713-722
Association of milk intake with hay fever, asthma, and lung function: a Mendelian randomization analysis
Background Previous observational studies have indicated a protective effect of drinking milk on asthma and allergy. In Mendelian Randomization, one or more genetic variants are used as unbiased markers of exposure to examine causal effects. We examined the causal effect of milk intake on hay fever, asthma, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) by using the lactase rs4988235 genotype associated with milk intake. Methods We performed a Mendelian Randomization study including 363,961 participants from the UK Biobank. Results Observational analyses showed that self-reported milk-drinkers vs. non-milk drinkers had an increased risk of hay fever: odds ratio (OR) = 1.36 (95% CI 1.32, 1.40, p < 0.001), asthma: OR = 1.33 (95% CI 1.38, 1.29, p < 0.001), yet a higher FEV1: β = 0.022 (SE = 0.004, p < 0.001) and FVC: β = 0.026 (SE = 0.005, p < 0.001). In contrast, genetically determined milk-drinking vs. not drinking milk was associated with a lower risk of hay fever: OR = 0.791 (95% CI 0.636, 0.982, p = 0.033), and asthma: OR = 0.587 (95% CI 0.442, 0.779, p = 0.001), and lower FEV1: β = − 0.154 (standard error, SE = 0.034, p < 0.001) liter, and FVC: β = − 0.223 (SE = 0.034, p < 0.001) liter in univariable MR analyses. These results were supported by multivariable Mendelian randomization analyses although not statistically significant. Conclusions As opposed to observational results, genetic association findings indicate that drinking milk has a protective effect on hay fever and asthma but may also have a negative effect on lung function. The results should be confirmed in other studies before any recommendations can be made.
Allergic rhinitis and allergic sensitisation are still increasing among Danish adults
Background: Only a limited number of studies have included objective measures of allergic sensitisation (such as skin‐prick test [SPT] and serum specific IgE [sIgE]) when studying time trends in allergic respiratory disease in adults within the current millennium.Methods: Five health examination studies of random samples of individuals aged 18‐69 years resident in the Copenhagen region were conducted in 1990‐1991, 2006‐2008, 2010‐2011, 2012‐2015, and 2016‐2017. Allergic sensitisation was defined by sIgE (in 1990‐1991, 2006‐2008, and, 2012‐2015) or SPT (in 2006‐2008, 2010‐2011, and 2016‐2017) to at least one of the allergens: birch, grass, house dust mite, or cat. Allergic rhinitis was defined as sensitisation and self‐reported nasal symptoms.Results: The age‐ and sex‐standardised prevalence of sIgE‐defined sensitisation increased from 16% in 1990‐1991, to 26% in 2006‐2008, and to 29% in 2012‐2015. The age‐ and sex‐standardised prevalence of SPT‐defined sensitisation increased from 27% in 2006‐2008, to 28% in 2010‐2011, and to 32% in 2016‐2017. Changes in sIgE‐defined and SPT‐defined allergic rhinitis showed similar increasing trends.Conclusion: The prevalence of allergic sensitisation and allergic rhinitis increased in a general adult Danish population over the last three decades and has thus continued to increase in the current millennium.
Allergic rhinitis and allergic sensitisation are still increasing among Danish adults
Background: Only a limited number of studies have included objective measures of allergic sensitisation (such as skin‐prick test [SPT] and serum specific IgE [sIgE]) when studying time trends in allergic respiratory disease in adults within the current millennium.Methods: Five health examination studies of random samples of individuals aged 18‐69 years resident in the Copenhagen region were conducted in 1990‐1991, 2006‐2008, 2010‐2011, 2012‐2015, and 2016‐2017. Allergic sensitisation was defined by sIgE (in 1990‐1991, 2006‐2008, and, 2012‐2015) or SPT (in 2006‐2008, 2010‐2011, and 2016‐2017) to at least one of the allergens: birch, grass, house dust mite, or cat. Allergic rhinitis was defined as sensitisation and self‐reported nasal symptoms.Results: The age‐ and sex‐standardised prevalence of sIgE‐defined sensitisation increased from 16% in 1990‐1991, to 26% in 2006‐2008, and to 29% in 2012‐2015. The age‐ and sex‐standardised prevalence of SPT‐defined sensitisation increased from 27% in 2006‐2008, to 28% in 2010‐2011, and to 32% in 2016‐2017. Changes in sIgE‐defined and SPT‐defined allergic rhinitis showed similar increasing trends.Conclusion: The prevalence of allergic sensitisation and allergic rhinitis increased in a general adult Danish population over the last three decades and has thus continued to increase in the current millennium.
Association of alcohol consumption with allergic disease and asthma: a multi‐centre Mendelian randomization analysis
Aims: To use the rs1229984 variant associated with alcohol consumption as an instrument for alcohol consumption to test the causality of the association of alcohol consumption with hay fever, asthma, allergic sensitization and serum total immunoglobulin (Ig)E. Design: Observational and Mendelian randomization analyses using genetic variants as unbiased markers of exposure to estimate causal effects, subject to certain assumptions. Setting: Europe. Participants: We included a total of 466 434 people aged 15–82 years from 17 population‐based studies conducted from 1997 to 2015. Measurements: The rs1229984 ( ADH1B ) was genotyped; alcohol consumption, hay fever and asthma were self‐reported. Specific and total IgE were measured from serum samples. Findings: Observational analyses showed that ever‐drinking versus non‐drinking, but not amount of alcohol intake, was positively associated with hay fever and inversely associated with asthma but not with allergic sensitization or serum total immunoglobulin (Ig)E. However, Mendelian randomization analyses did not suggest that the observational associations are causal. The causal odds ratio (OR) per genetically assessed unit of alcohol/week was an OR = 0.907 [95% confidence interval (CI) = 0.806, 1.019; P = 0.101] for hay fever, an OR = 0.897 (95% CI = 0.790, 1.019; P = 0.095) for asthma, an OR = 0.971 (95% CI = 0.804, 1.174; P = 0.763) for allergic sensitization and a 4.7% change (95% CI = –5.5%, 14.9%; P = 0.366) for total IgE. Conclusions: In observational analyses, ever‐drinking versus not drinking was positively associated with hay fever and negatively associated with asthma. However, the Mendelian randomization results were not consistent with these associations being causal.
Association of alcohol consumption with allergic disease and asthma: a multi‐centre Mendelian randomization analysis
Aims: To use the rs1229984 variant associated with alcohol consumption as an instrument for alcohol consumption to test the causality of the association of alcohol consumption with hay fever, asthma, allergic sensitization and serum total immunoglobulin (Ig)E. Design: Observational and Mendelian randomization analyses using genetic variants as unbiased markers of exposure to estimate causal effects, subject to certain assumptions. Setting: Europe. Participants: We included a total of 466 434 people aged 15–82 years from 17 population‐based studies conducted from 1997 to 2015. Measurements: The rs1229984 ( ADH1B ) was genotyped; alcohol consumption, hay fever and asthma were self‐reported. Specific and total IgE were measured from serum samples. Findings: Observational analyses showed that ever‐drinking versus non‐drinking, but not amount of alcohol intake, was positively associated with hay fever and inversely associated with asthma but not with allergic sensitization or serum total immunoglobulin (Ig)E. However, Mendelian randomization analyses did not suggest that the observational associations are causal. The causal odds ratio (OR) per genetically assessed unit of alcohol/week was an OR = 0.907 [95% confidence interval (CI) = 0.806, 1.019; P = 0.101] for hay fever, an OR = 0.897 (95% CI = 0.790, 1.019; P = 0.095) for asthma, an OR = 0.971 (95% CI = 0.804, 1.174; P = 0.763) for allergic sensitization and a 4.7% change (95% CI = –5.5%, 14.9%; P = 0.366) for total IgE. Conclusions: In observational analyses, ever‐drinking versus not drinking was positively associated with hay fever and negatively associated with asthma. However, the Mendelian randomization results were not consistent with these associations being causal.
- 1 September 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (5) , 768-775
Spatial QRS-T angle variants for prediction of all-cause mortality
- 1 September 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (5) , 768-775
Spatial QRS-T angle variants for prediction of all-cause mortality
- Open Access
- 1 July 2018
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 10, 763-770
Trends in treatments of thyroid disease following iodine fortification in Denmark: a nationwide register-based study
Background: Long-term iodine exposure may influence the frequency of thyroid disease treatments through fluctuations in thyroid diseases. Yet, the long-term fluctuations in thyroid disease treatments upon iodine fortification (IF) are not fully known. We aimed to examine the development in thyroid disease treatments in Denmark before and following the implementation of IF in 2000. Methods: Nationwide data on antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment were obtained from Danish registries. Negative binominal regression was applied to analyze annual changes in treatment rates adjusted for region of residence, sex, and age. Results: Incidence of antithyroid medication transiently increased but fell and reached steady state from 2010 at an incidence rate ratio (RR) of 0.72 (95% confidence interval [CI] 0.67–0.77) compared to year 2000. Thyroid hormone therapy increased and reached steady state in 2010 at an incidence RR of 1.75 (95% CI 1.62–1.89) compared to year 2000. Thyroid surgery was constant except for higher rates in 2014–2015, and radioiodine treatment fluctuated with no apparent pattern. Conclusion: Ten years after IF, a steady state was observed for incident antithyroid medication below the level at IF, and thyroid hormone therapy above the level at IF. Only small changes were observed in thyroid surgery and radioiodine treatment. In the same period, changes in diagnostic and treatment practices and lifestyle factors are likely to have occurred and should be considered when evaluating the effects of IF on treatment of thyroid diseases.
- 1 July 2018
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 10, 763-770
Open AccessTrends in treatments of thyroid disease following iodine fortification in Denmark: a nationwide register-based study
Background: Long-term iodine exposure may influence the frequency of thyroid disease treatments through fluctuations in thyroid diseases. Yet, the long-term fluctuations in thyroid disease treatments upon iodine fortification (IF) are not fully known. We aimed to examine the development in thyroid disease treatments in Denmark before and following the implementation of IF in 2000. Methods: Nationwide data on antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment were obtained from Danish registries. Negative binominal regression was applied to analyze annual changes in treatment rates adjusted for region of residence, sex, and age. Results: Incidence of antithyroid medication transiently increased but fell and reached steady state from 2010 at an incidence rate ratio (RR) of 0.72 (95% confidence interval [CI] 0.67–0.77) compared to year 2000. Thyroid hormone therapy increased and reached steady state in 2010 at an incidence RR of 1.75 (95% CI 1.62–1.89) compared to year 2000. Thyroid surgery was constant except for higher rates in 2014–2015, and radioiodine treatment fluctuated with no apparent pattern. Conclusion: Ten years after IF, a steady state was observed for incident antithyroid medication below the level at IF, and thyroid hormone therapy above the level at IF. Only small changes were observed in thyroid surgery and radioiodine treatment. In the same period, changes in diagnostic and treatment practices and lifestyle factors are likely to have occurred and should be considered when evaluating the effects of IF on treatment of thyroid diseases.
- Open Access
Exome wide association study on Albuminuria identifies a novel rare variant in CUBN and additional genes, in 33985 Europeans with and without diabetes
Identifying rare coding variants associated with albuminuria may open new avenues for preventing chronic kidney disease (CKD) and end-stage renal disease which are highly prevalent in patients with diabetes. Efforts to identify genetic susceptibility variants for albuminuria have so far been limited with the majority of studies focusing on common variants. We performed an exome-wide association study to identify coding variants in a two phase (discovery and replication) approach, totaling to 33,985 individuals of European ancestry (15,872 with and 18,113 without diabetes) and further testing in Greenlanders (n = 2,605). We identify a rare (MAF: 0.8%) missense (A1690V) variant in CUBN (rs141640975, β=0.27, p=1.3 × 10 −11 ) associated with albuminuria as a continuous measure in the combined European meta-analyses. Presence of each rare allele of the variant was associated with a 6.4% increase in albuminuria. The rare CUBN variant had 3 times stronger effect in individuals with diabetes compared to those without (pinteraction: 5.4 × 10 −4 , β DM : 0.69, β nonDM: 0.20) in the discovery meta-analyses. Geneaggregate tests based on rare and common variants identify three additional genes associated with albuminuria (HES1, CDC73 , and GRM5) after multiple testing correction ( P _ bonferroni −6 ). The current study identifies a rare coding variant in the CUBN locus and other potential genes associated with albuminuria in individuals with and without diabetes. These genes have been implicated in renal and cardiovascular dysfunction. These findings provide new insights into the genetic architecture of albuminuria and highlight novel target genes and pathways for prevention of diabetes-related kidney disease. Significance statement: Increased albuminuria is a key manifestation of major health burdens, including chronic kidney disease and/or cardiovascular disease. Although being partially heritable, there is a lack of knowledge on rare genetic variants that contribute to albuminuria. The current study describes the discovery and validation, of a new rare gene mutation (~1%) in the CUBN gene which associates with increased albuminuria. Its effect multiplies 3 folds among diabetes cases compared to non diabetic individuals. The study further uncovers 3 additional genes modulating albuminuria levels in humans. Thus the current study findings provide new insights into the genetic architecture of albuminuria and highlight novel genes/pathways for prevention of diabetes related kidney disease.
Open AccessExome wide association study on Albuminuria identifies a novel rare variant in CUBN and additional genes, in 33985 Europeans with and without diabetes
Identifying rare coding variants associated with albuminuria may open new avenues for preventing chronic kidney disease (CKD) and end-stage renal disease which are highly prevalent in patients with diabetes. Efforts to identify genetic susceptibility variants for albuminuria have so far been limited with the majority of studies focusing on common variants. We performed an exome-wide association study to identify coding variants in a two phase (discovery and replication) approach, totaling to 33,985 individuals of European ancestry (15,872 with and 18,113 without diabetes) and further testing in Greenlanders (n = 2,605). We identify a rare (MAF: 0.8%) missense (A1690V) variant in CUBN (rs141640975, β=0.27, p=1.3 × 10 −11 ) associated with albuminuria as a continuous measure in the combined European meta-analyses. Presence of each rare allele of the variant was associated with a 6.4% increase in albuminuria. The rare CUBN variant had 3 times stronger effect in individuals with diabetes compared to those without (pinteraction: 5.4 × 10 −4 , β DM : 0.69, β nonDM: 0.20) in the discovery meta-analyses. Geneaggregate tests based on rare and common variants identify three additional genes associated with albuminuria (HES1, CDC73 , and GRM5) after multiple testing correction ( P _ bonferroni −6 ). The current study identifies a rare coding variant in the CUBN locus and other potential genes associated with albuminuria in individuals with and without diabetes. These genes have been implicated in renal and cardiovascular dysfunction. These findings provide new insights into the genetic architecture of albuminuria and highlight novel target genes and pathways for prevention of diabetes-related kidney disease. Significance statement: Increased albuminuria is a key manifestation of major health burdens, including chronic kidney disease and/or cardiovascular disease. Although being partially heritable, there is a lack of knowledge on rare genetic variants that contribute to albuminuria. The current study describes the discovery and validation, of a new rare gene mutation (~1%) in the CUBN gene which associates with increased albuminuria. Its effect multiplies 3 folds among diabetes cases compared to non diabetic individuals. The study further uncovers 3 additional genes modulating albuminuria levels in humans. Thus the current study findings provide new insights into the genetic architecture of albuminuria and highlight novel genes/pathways for prevention of diabetes related kidney disease.
- 1 June 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (6) , 594-600
Screen-detected gallstone disease and autoimmune diseases — A cohort study
- 1 June 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (6) , 594-600
Screen-detected gallstone disease and autoimmune diseases — A cohort study
- 7 February 2018
- Published by Springer Nature in Endocrine
- Vol. 60 (1) , 122-128
A randomized general population study of the effects of repeated health checks on incident diabetes
It is not clear whether offering health checks to the general population can be used to prevent diabetes. Few randomized studies have had a long-term follow-up. We used a randomly selected population cohort as a randomized trial to examine the effect of repeated health checks on the 30-year incidence of diabetes.
- 7 February 2018
- Published by Springer Nature in Endocrine
- Vol. 60 (1) , 122-128
A randomized general population study of the effects of repeated health checks on incident diabetes
It is not clear whether offering health checks to the general population can be used to prevent diabetes. Few randomized studies have had a long-term follow-up. We used a randomly selected population cohort as a randomized trial to examine the effect of repeated health checks on the 30-year incidence of diabetes.